Skip to content
10-K

Annual Report

Curanex Pharmaceuticals Inc CURX

0001493152-26-013677

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 30, 2026 28.36M sh
Shares Diluted FY 2025 · Dec 31, 2025 25.5M sh
Shares Diluted FY 2025 · Dec 31, 2024 13.26M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$10.48M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$555.58K
Cash And Equivalents FY 2025 · Dec 31, 2025 $5M
Stockholders Equity FY 2025 · Dec 31, 2025 $11.22M
Stockholders Equity FY 2025 · Dec 31, 2024 $503.36K
Stockholders Equity FY 2025 · Dec 31, 2023 $60.09K
Current Liabilities FY 2025 · Dec 31, 2025 $137.03K
Current Liabilities FY 2025 · Dec 31, 2024 $14.58K
Total Liabilities FY 2025 · Dec 31, 2025 $361.04K
Total Liabilities FY 2025 · Dec 31, 2024 $14.58K
Current Assets FY 2025 · Dec 31, 2025 $11.23M
Current Assets FY 2025 · Dec 31, 2024 $517.94K
Total Assets FY 2025 · Dec 31, 2025 $11.58M
Total Assets FY 2025 · Dec 31, 2024 $517.94K
Eps Diluted FY 2025 · Dec 31, 2025 −$0.17
Eps Diluted FY 2025 · Dec 31, 2024 −$0.03
Eps Basic FY 2025 · Dec 31, 2025 −$0.17
Eps Basic FY 2025 · Dec 31, 2024 −$0.03
Sga Expense FY 2025 · Dec 31, 2025 $1.25M
Sga Expense FY 2025 · Dec 31, 2024 $290.39K
Rd Expense FY 2025 · Dec 31, 2025 $2.99M
Net Income FY 2025 · Dec 31, 2025 −$4.23M
Net Income FY 2025 · Dec 31, 2024 −$361.51K
Operating Income FY 2025 · Dec 31, 2025 −$4.24M
Operating Income FY 2025 · Dec 31, 2024 −$365.06K